Welcome to our dedicated page for Sagimet Biosciences SEC filings (Ticker: SGMT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a biotech filing packed with drug-trial data and cash-runway tables can drain hours. Sagimet Biosciences’ 10-K alone layers complex R&D footnotes over dense risk factors tied to its FASN program. If you are searching “Sagimet Biosciences SEC filings explained simply” or wondering how Form 4 insider trades may signal management’s confidence, you have likely met this challenge.
Stock Titan solves it. Our AI reads every Sagimet Biosciences annual report 10-K, quarterly earnings report 10-Q filing, and 8-K material event the moment EDGAR posts them. It then delivers concise, plain-English summaries that highlight R&D spend, denifanstat trial milestones, and liquidity updates—exactly what analysts look for. Real-time alerts flag “Sagimet Biosciences insider trading Form 4 transactions” so you can track executive stock moves without sifting through PDFs. Need quick answers? Ask, “Where is Sagimet Biosciences’ proxy statement executive compensation?” and our platform directs you to the page and provides context.
Investors use these insights to:
- Compare quarter-over-quarter clinical expenses across business segments
- Monitor “Sagimet Biosciences Form 4 insider transactions real-time” for buying or selling patterns
- Decode 8-K disclosures on trial results or financing agreements within minutes
Whether you are analysing a fresh 10-Q or revisiting a past 10-K, Stock Titan delivers comprehensive coverage, AI-powered summaries, and expert analysis so you can understand Sagimet Biosciences filings quickly and act with confidence.
Sagimet Biosciences (SGMT) received an Amendment No. 1 to Schedule 13G from AP11 Limited and Ascletis Pharma Inc., dated 24 June 2025 and filed 29 June 2025. The filing reports beneficial ownership of 1,504,642 Series A common shares, equal to 4.9 % of the 30,674,855 shares outstanding as cited in Sagimet’s 10 June 2025 Form 8-K.
The reporting persons each claim sole voting and dispositive power over the entire position and report no shared power and no group status. Item 5 confirms “ownership of 5 percent or less,” meaning the investors are no longer 5 % holders under SEC rules. No additional transactions, control arrangements, or contingent rights are disclosed, and the document contains no risk factors, legal matters, or financial projections.
Overall, the amendment simply updates Sagimet’s ownership ledger, signalling that two related offshore entities now hold a sub-5 % passive stake without seeking influence over the issuer’s governance.
FAQ
What is the current stock price of Sagimet Biosciences (SGMT)?
What is the market cap of Sagimet Biosciences (SGMT)?
What is the core focus of Sagimet Biosciences Inc.?
What is denifanstat and why is it significant?
How does Sagimet generate value through its technology?
What clinical programs are currently emphasized by the company?
How does Sagimet differentiate itself from other biopharmaceutical companies?
Are there additional therapeutic areas beyond liver diseases in Sagimet's pipeline?
What role do clinical trials play in Sagimet’s development strategy?
How does the company ensure scientific rigor and reliability?
What is the overall market significance of Sagimet Biosciences Inc.?
